EISAI ANNOUNCES ESTABLISHMENT OF A PHARMACEUTICALS MARKETING SUBSIDIARY IN SWEDEN

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced on July 8, 2005, the establishment of a pharmaceuticals marketing subsidiary, Eisai AB, in Sweden to expand business in the four Nordic countries (Sweden, Denmark, Finland and Norway). Eisai AB is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya). In the Nordic market, Eisai AB plans to sell and promote pharmaceuticals mainly in the neurology area including the anti-epileptic drugs Zonegran and Inovelon, for which a marketing application has been submitted to the European Medicines Evaluation Agency. The newly established subsidiary company will also promote active business development, and aims at establishing an efficient and profitable business framework.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=256193&categoryid=54)